[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
March 23, 1994

New Vaccine Technologies

Author Affiliations

From Merck Research Laboratories, West Point, Pa (Dr Ellis) and Merck Vaccine Division (Dr Douglas), Merck & Co Inc, Whitehouse Station, NJ.

JAMA. 1994;271(12):929-931. doi:10.1001/jama.1994.03510360055036

PREVENTION of disease is a tenet of all the various approaches to health care reform. One of the most effective medical interventions ever devised are vaccines, with their high level of benefit and cost-effectiveness for public health. There has never been a more exciting time for vaccine research and development, largely as a result of the implementation and refinement of a variety of new technologies. Several new vaccines have been licensed recently in different countries for routine use, including recombinant hepatitis B (HB), Haemophilus influenzae type b (Hib) conjugate, and hepatitis A (HA) vaccines. Several more are expected to be licensed throughout the 1990s, including acellular pertussis (for infants), varicella, and pneumococcal conjugate vaccines. Of potentially greater importance are several technological developments that, if successful, would revolutionize the way in which vaccines are produced and used. This article reviews three such developments, each of which is being researched and developed

First Page Preview View Large
First page PDF preview
First page PDF preview